Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, PR positive status confers therapeutic sensitivity to Letrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior standard adjuvant tamoxifen therapy for 5 years.
This statement is based on a regulatory approval from the Health Products Regulatory Authority:
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.